Outcomes
Three of the 57 patients (5%) had concurrent diagnoses of NLPHL; all
three were treated with chemotherapy. Another three patients (5%) had
completed therapy for prior history of malignancy two or more years
prior to PTGC diagnosis; one with recurrent NLPHL, one with classic
Hodgkin lymphoma (CHL), and one with T-cell/histiocyte-rich large B-cell
lymphoma. No patients went on to be diagnosed with a subsequent
malignancy during the study period, but 3/57 (5%) patients had
recurrent PTGC. Repeat LN biopsy for these three individuals was
performed at intervals of three months, four months, and six years from
the first biopsy.
One patient had prior history of common variable immunodeficiency (CVID)
managed at an outside center and one had history of refractory Evans
syndrome treated with steroids and rituximab; due to history of bulky
lymphadenopathy, this patient was being evaluated for ALPS. An
additional patient developed a subsequent diagnosis of Type 1 diabetes
mellitus during the inclusion period. No other immune-mediated or
lymphoproliferative conditions were documented in these patients during
the inclusion period.